Involvement of insulin-like growth factor-I in the control of glucose homeostasis

Current Opinion in Pharmacology

Volumn 6, Issue 6, 2006, Pages 620-625

  Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR BLOCKING AGENT; HYPERGLYCEMIC AGENT; INSULIN; INSULIN GLARGINE; INSULIN RECEPTOR; LONG ACTING INSULIN; PROINSULIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ACROMEGALY; ARTHRALGIA; BINDING AFFINITY; DRUG ACTIVITY; EDEMA; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GENETIC MANIPULATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONAL REGULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN LIKE ACTIVITY; INSULIN SENSITIVITY; KIDNEY PARENCHYMA; METABOLIC REGULATION; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SKELETAL MUSCLE; STRUCTURAL HOMOLOGY; TISSUE SPECIFICITY;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I;

EID: 33751059804     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.08.006     Document Type: Review

References (50)

1. Rinderknecht E., and Humbel R.E. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253 (1978) 2769-2776
2. Blundell T.L., Bedarkar S., and Humbel R.E. Tertiary structures, receptor binding, and antigenicity of insulinlike growth factors. Fed Proc 42 (1983) 2592-2597
3. Cascieri M.A., and Bayne M.L. Analysis of the interaction of IGF-I analogs with the IGF-I receptor and IGF binding proteins. Adv Exp Med Biol 343 (1993) 33-40
4. Hartman M.L., Clayton P.E., Johnson M.L., Celniker A., Perlman A.J., Alberti K.G., and Thorner M.O. A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. J Clin Invest 91 (1993) 2453-2462
5. Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell 120 (2005) 449-460. This paper provides a simple framework for understanding how the insulin/IGF-I system functions in primitive organisms.
6. Merimee T.J., Zapf J., and Froesch E.R. Insulin-like growth factors in the fed and fasted states. J Clin Endocrinol Metab 55 (1982) 999-1002
7. Underwood L.E., Thissen J.P., Lemozy S., Ketelslegers J.M., and Clemmons D.R. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 42 (1994) 145-151
8. Pao C.I., Farmer P.K., Begovic S., Goldstein S., Wu G.J., and Phillips L.S. Expression of hepatic insulin-like growth factor-I and insulin-like growth factor-binding protein-1 genes is transcriptionally regulated in streptozotocin-diabetic rats. Mol Endocrinol 6 (1992) 969-977
9. Hanaire-Broutin H., Sallerin-Caute B., Poncet M.F., Tauber M., Bastide R., Chale J.J., Rosenfeld R., and Tauber J.P. Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM. Diabetologia 39 (1996) 1498-1504
10. Clemmons D.R. Role of insulin-like growth factor in maintaining normal glucose homeostasis. Horm Res 62 Suppl 1 (2004) 77-82
11. Nakae J., Kido Y., and Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 22 (2001) 818-835
12. Vary T.C., and Lang C.H. IGF-I activates the eIF4F system in cardiac muscle in vivo. Mol Cell Biochem 272 (2005) 209-220
13. Soos M.A., Field C.E., and Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 290 (1993) 419-426
14. Li G., Barrett E.J., Wang H., Chai W., and Liu Z. Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. Endocrinology 146 (2005) 4690-4696
15. Federici M., Giaccari A., Hribal M.L., Giovannone B., Lauro D., Morviducci L., Pastore L., Tamburrano G., Lauro R., and Sesti G. Evidence for glucose/hexosamine in vivo regulation of insulin/IGF-I hybrid receptor assembly. Diabetes 48 (1999) 2277-2285
16. Federici M., Porzio O., Zucaro L., Giovannone B., Borboni P., Marini M.A., Lauro D., and Sesti G. Increased abundance of insulin/IGF-I hybrid receptors in adipose tissue from NIDDM patients. Mol Cell Endocrinol 135 (1997) 41-47
17. Guler H.P., Zapf J., and Froesch E.R. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317 (1987) 137-140
18. Saukkonen T., Shojaee-Moradie F., Williams R.M., Amin R., Yuen K.C., Watts A., Acerini C.L., Umpleby A.M., and Dunger D.B. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Diabetes 55 (2006) 2365-2370
19. Holt R.I., Simpson H.L., and Sonksen P.H. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med 20 (2003) 3-15
20. Morrow L.A., O'Brien M.B., Moller D.E., Flier J.S., and Moses A.C. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 79 (1994) 205-210
21. Kuzuya H., Matsuura N., Sakamoto M., Makino H., Sakamoto Y., Kadowaki T., Suzuki Y., Kobayashi M., Akazawa Y., Nomura M., et al. Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42 (1993) 696-705
22. Firth S.M., McDougall F., McLachlan A.J., and Baxter R.C. Impaired blockade of insulin-like growth factor I (IGF-I)-induced hypoglycemia by IGF binding protein-3 analog with reduced ternary complex-forming ability. Endocrinology 143 (2002) 1669-1676
23. Young S.C., and Clemmons D.R. Changes in insulin-like growth factor (IGF)-binding proteins after IGF-I injections in noninsulin-dependent diabetics. J Clin Endocrinol Metab 78 (1994) 609-614
24. Murphy L.J. The role of the insulin-like growth factors and their binding proteins in glucose homeostasis. Exp Diabesity Res 4 (2003) 213-224
25. Cusi K., and DeFronzo R. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab 85 (2000) 3077-3084
26. Mauras N., O'Brien K.O., Welch S., Rini A., Helgeson K., Vieira N.E., and Yergey A.L. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 85 (2000) 1686-1694
27. Baker J., Liu J.P., Robertson E.J., and Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75 (1993) 73-82
28. Yakar S., Liu J.L., Stannard B., Butler A., Accili D., Sauer B., and LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96 (1999) 7324-7329
29. Sjogren K., Liu J.L., Blad K., Skrtic S., Vidal O., Wallenius V., LeRoith D., Tornell J., Isaksson O.G., Jansson J.O., et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 96 (1999) 7088-7092
30. O'Connell T., and Clemmons D.R. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab 87 (2002) 4356-4360
31. Yakar S., Setser J., Zhao H., Stannard B., Haluzik M., Glatt V., Bouxsein M.L., Kopchick J.J., and LeRoith D. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 113 (2004) 96-105
32. Fernandez A.M., Kim J.K., Yakar S., Dupont J., Hernandez-Sanchez C., Castle A.L., Filmore J., Shulman G.I., and Le Roith D. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15 (2001) 1926-1934
33. Pennisi P., Gavrilova O., Setser-Portas J., Jou W., Santopietro S., Clemmons D., Yakar S., and Leroith D. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147 (2006) 2619-2630. This paper provides strong evidence in support of the conclusion that IGF-I lowers fasting glucose by suppressing renal gluconeogenesis.
34. Rietveld I., Janssen J.A., van Rossum E.F., Houwing-Duistermaat J.J., Rivadeneira F., Hofman A., Pols H.A., van Duijn C.M., and Lamberts S.W. A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. Clin Endocrinol (Oxf) 61 (2004) 195-203
35. Vaessen N., Heutink P., Janssen J.A., Witteman J.C., Testers L., Hofman A., Lamberts S.W., Oostra B.A., Pols H.A., and van Duijn C.M. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 50 (2001) 637-642
36. Juul A., Scheike T., Davidsen M., Gyllenborg J., and Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106 (2002) 939-944
37. Iniguez G., Ong K., Bazaes R., Avila A., Salazar T., Dunger D., and Mericq V. Longitudinal changes in IGF-I, insulin sensitivity and secretion from birth to age three years in small-for-gestational-age children. J Clin Endocrinol Metab (2006) [Aug 15th, e-pub ahead of print]
38. Verkauskiene R., Jaquet D., Deghmoun S., Chevenne D., Czernichow P., and Levy-Marchal C. Smallness for gestational age is associated with persistent change in insulin-like growth factor I (IGF-I) and the ratio of IGF-I/IGF-binding protein-3 in adulthood. J Clin Endocrinol Metab 90 (2005) 5672-5676. This study shows that, if changes in the IGF-I system are present at birth in children who are SGA, and they persist into adolescence, they may correlate with the development of insulin resistance that occurs in the children as they enter adulthood.
39. Tenhola S., Halonen P., Jaaskelainen J., and Voutilainen R. Serum markers of GH and insulin action in 12-year-old children born small for gestational age. Eur J Endocrinol 152 (2005) 335-340
40. Saukkonen T., Amin R., Williams R.M., Fox C., Yuen K.C., White M.A., Umpleby A.M., Acerini C.L., and Dunger D.B. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 89 (2004) 4634-4641. This paper documents that IGF-I suppression of GH in diabetes contributes to its ability to suppress hepatic glucose output.
41. Strasser-Vogel B., Blum W.F., Past R., Kessler U., Hoeflich A., Meiler B., and Kiess W. Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment. J Clin Endocrinol Metab 80 (1995) 1207-1213
42. Quattrin T., Thrailkill K., Baker L., Litton J., Dwigun K., Rearson M., Poppenheimer M., Giltinan D., Gesundheit N., and Martha Jr. P. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile. Diabetes Care 20 (1997) 374-380
43. Thrailkill K.M., Quattrin T., Baker L., Kuntze J.E., Compton P.G., and Martha Jr. P.M. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group. Diabetes Care 22 (1999) 585-592
44. Clemmons D.R., Moses A.C., McKay M.J., Sommer A., Rosen D.M., and Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 85 (2000) 1518-1524
45. Moses A.C., Young S.C., Morrow L.A., O'Brien M., and Clemmons D.R. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45 (1996) 91-100
46. Rh in NIDDM Study Group. Evidence from a dose ranging study that recombinant insulin-like growth factor-I (RhIGF-I) effectively and safely improves glycemic control in the non-insulin dependent diabetes mellitus. Diabetes 45 (1996) 91-100
47. RhIGF-I co therapy with Insulin Subgroup: RhIGF-I improves glucose control in insulin requiring type 2 diabetes. Proceedings of the 5th Annual Meeting of The American Diabetes Association, San Antonio, Texas, 1997. [Abstract 582].
48. Clemmons D.R., Moses A.C., Sommer A., Jacobson W., Rogol A.D., Sleevi M.R., and Allan G. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 15 (2005) 265-274. The study confirms that IGF-I is effective at lowering blood glucose in type II diabetes, and shows that this response requires relatively high concentrations of free IGF-I.
49. Renehan A.G., Harvie M., and Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer ris: eight years on. Endocr Relat Cancer 13 (2006) 273-278
50. Backeljauw P.F., and Underwood L.E. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 86 (2001) 1504-1510